TABLE 4.
Antimicrobial susceptibility to BLBLIs
| Pathogen (no. of isolates, source [reference]) | Yr published | Sample collection yr(s) | % of isolates susceptible to:a
|
|||
|---|---|---|---|---|---|---|
| CAZ-AVI | TOL-TAZ | MER-VAB | IMI-REL | |||
| Pseudomonas aeruginosa | ||||||
| n = 14,330, globally (277) | 2020 | 2012–2016 | 91.5b | |||
| n = 3,193, U.S. (182) | 2020 | 2014–2018 | 88.8–89.5c | |||
| n = 1,445, Spain (220) | 2020 | 2017 | 94.2b | 94.6b | 97.3b | |
| n = 414, globally (278) | 2020 | 93.0c | 97.0c | |||
| n = 1,513, U.S. (124) | 2019 | 2012–2016 | 97.5b,c | |||
| n = 413, globally (127) | 2019 | 2012–2016 | 93.2b ,c | |||
| n = 80, Spain (279) | 2019 | 2016–2017 | 91.3b ,c | |||
| n = 188, Italy (280) | 2019 | 2010–2016 | 85.1b | |||
| n = 1,794, Latin America (281) | 2019 | 2012–2015 | 87.4c | |||
| n = 100, Taiwan (282) | 2019 | 2016–2019 | 91.0c | 93.0c | ||
| n = 2,215, U.S. (276) | 2019 | 2017–2018 | 96.0b ,c | 95.9b ,c | ||
| n = 433, U.S. (283) | 2019 | 2015–2017 | 98.2b ,c | 98.7b ,c | ||
| n = 524, China (128) | 2019 | 2017 | 86.5c | 88.5c | ||
| n = 12,170, globally (284) | 2019 | 2012–2016 | 90.8c | |||
| n = 896, U.S. (208) | 2018 | 2016 | 94.4d | |||
| n = 1,705, Europe (285) | 2018 | 2015 | 94.7c | |||
| n = 3,229, Canada (126) | 2018 | 2008–2016 | 98.3c | |||
| n = 355, U.S. (286) | 2018 | 2013–2015 | 97.5c | |||
| n = 1,909, U.S. (287) | 2018 | 2017 | 96.9b ,c | 97.5b ,c | ||
| n = 100, Australia (288) | 2018 | 2008–2018 | 96.0b ,c | |||
| n = 368, China (289) | 2018 | 2012–2014 | 75.6c | |||
| n = 1,259, U.S. (22) | 2018 | 2015–2017 | 96.8c | |||
| n = 423, U.S. (22) | 2018 | 2017 | 96.2c | 96.5c | ||
| n = 5,716, Europe (290) | 2018 | 2012–2015 | 92.4b | |||
| n = 56, globally (84) | 2018 | 66.1c | ||||
| n = 4,175, U.S. (37) | 2018 | 2015–2016 | 97.6c | |||
| n = 4,175, U.S. (291) | 2018 | 2011–2015 | 96.5c | |||
| n = 935, Italy (292) | 2018 | 2013–2014 | 90.9c | |||
| n = 3,737, U.S. (293) | 2018 | 2013–2016 | 97.3b ,c | |||
| n = 489, Asia-Pacific Region (125) | 2018 | 2013–2015 | 90.8b ,c | |||
| n = 598, U.S. (294) | 2017 | 2015 | 93.1c | |||
| n = 16, globally (225) | 2017 | 2012–2015 | 100.0c | |||
| n = 603, Europe (295) | 2017 | 2012–2015 | 91.7b | |||
| n = 1,099, United Kingdom (119) | 2017 | 2011–2015 | 99.8b | |||
| n = 537, Latin America (296) | 2017 | 2013–2015 | 86.8b ,c | |||
| n = 7,868, U.S. (24) | 2017 | 2013–2016 | 97.1b ,c | |||
| n = 3,402, U.S. (30) | 2017 | 2011–2015 | 96.6b ,c | |||
| n = 440, Australia/New Zealand (297) | 2017 | 2013–2015 | 95.7b ,c | |||
| n = 442, U.S. (298) | 2016 | 2012–2014 | 97.7c | |||
| n = 210, U.S. (299) | 2016 | 2012–2014 | 97.1c | |||
| n = 1,257, U.S. (123) | 2015 | 2013–2014 | 97.0c | |||
| n = 490, U.S. (216) | 2015 | 2013–2014 | 98.0c | |||
| n = 5,328, U.S. (300) | 2015 | 2011–2014 | 96.8c | |||
| Average susceptibility | 66.1–98.2 | 86.8–99.8 | 88.8–89.5 | 90.8–100.00 | ||
| Pseudomonas aeruginosa, MDR | ||||||
| n = 3,770, globally (277) | 2020 | 2012–2016 | 68.2b | |||
| n = 697, U.S. (182) | 2020 | 2014–2018 | 59.0–59.7c | |||
| n = 307, U.S. (124) | 2019 | 2012–2016 | 87.9b ,c | |||
| n = 20, Italy (280) | 2019 | 2010–2016 | 70.0b | |||
| n = 205, Qatar (301) | 2019 | 2014–2015 | 68.8c | 62.9c | ||
| n = 526, U.S. (276) | 2019 | 2017–2018 | 83.5b ,c | 83.7b ,c | ||
| n = 80, Germany (49) | 2019 | 2013–2018 | 85.0b | |||
| n = 750, U.S. (302) | 2019 | 2015–2017 | 79.7c | |||
| n = 3,708, globally (284) | 2019 | 2012–2016 | 70.7c | |||
| n = 462, Canada (126) | 2018 | 2008–2016 | 90.5c | |||
| n = 327, U.S. (22) | 2018 | 2015–2017 | 88.1c | |||
| n = 121, U.S. (22) | 2018 | 2017 | 86.2c | 87.6c | ||
| n = 879, U.S. (37) | 2018 | 2015–2016 | 89.3c | |||
| n = 32, U.S. (303) | 2018 | 2015 | 71.9c | |||
| n = 783, U.S. (293) | 2018 | 2013–2016 | 88.6b ,c | |||
| n = 134, Asia-Pacific Region (125) | 2018 | 2013–2015 | 67.2b ,c | |||
| n = 227, U.S. (208) | 2018 | 2016 | 82.2d | |||
| n = 44, Germany (304) | 2017 | 2013–2016 | 95.2b | |||
| n = 1,562, U.S. (24) | 2017 | 2013–2016 | 86.5b ,c | |||
| n = 47, Australia/New Zealand (297) | 2017 | 2013–2015 | 68.1b ,c | |||
| Average susceptibility | 68.2–89.3 | 62.9–95.2 | 59.0–59.7 | 70.7–82.2 | ||
| Pseudomonas aeruginosa, XDR | ||||||
| n = 1,652, globally (277) | 2020 | 2012–2016 | 43.0b | |||
| n = 440, U.S. (182) | 2020 | 2014–2018 | 47.1–48.6c | |||
| n = 193, U.S. (124) | 2019 | 2012–2016 | 82.9b ,c | |||
| n = 20, Italy (280) | 2019 | 2010–2016 | 58.1b | |||
| n = 326, U.S. (276) | 2019 | 2017–2018 | 78.2b ,c | 76.5b ,c | ||
| n = 112, Germany (49) | 2019 | 2013–2018 | 49.1b | |||
| n = 84, Canada (126) | 2018 | 2008–2016 | 78.6c | |||
| n = 145, U.S. (22) | 2018 | 2015–2017 | 78.6c | |||
| n = 54, U.S. (22) | 2018 | 2017 | 77.8c | 79.6c | ||
| n = 393, U.S. (37) | 2018 | 2015–2016 | 80.4c | |||
| n = 348, U.S. (293) | 2018 | 2013–2016 | 77.6b ,c | |||
| n = 44, Germany (304) | 2017 | 2013–2016 | 50.0b | |||
| n = 717, U.S. (24) | 2017 | 2013–2016 | 75.9b ,c | |||
| Average susceptibility | 43.0–80.4 | 50.0–82.9 | 47.1–48.6 | |||
| Pseudomonas aeruginosa, meropenem nonsusceptible | ||||||
| n = 73, Italy (280) | 2019 | 2010–2016 | 70.0b | |||
| n = 368, U.S. (124) | 2019 | 2012–2016 | 90.8b ,c | |||
| n = 614, Canada (126) | 2018 | 2008–2016 | 94.8c | |||
| n = 138, Asia-Pacific Region (125) | 2018 | 2013–2015 | 70.3b ,c | |||
| n = 712, U.S. (293) | 2018 | 2013–2016 | 88.6b ,c | |||
| n = 192, Latin America (296) | 2017 | 2013–2015 | 66.1b ,c | |||
| n = 31, Australia/New Zealand (297) | 2017 | 2013–2015 | 68.1b ,c | |||
| n = 126, Europe (295) | 2017 | 2012–2015 | 65.9b | |||
| Average susceptibility | 70.0 | 65.9–94.8 | ||||
| Pseudomonas aeruginosa, imipenem nonsusceptible | ||||||
| n = 3,776, globally (284) | 2019 | 2012–2016 | 70.3c | |||
| n = 227, U.S. (208) | 2018 | 2016 | 78.0d | |||
| n = 477, Europe (285) | 2018 | 2015 | 81.1c | |||
| n = 191, U.S. (294) | 2017 | 2015 | 78.5c | |||
| n = 144, U.S. (216) | 2015 | 2013–2014 | 92.0c | |||
| Average susceptibility | 70.3–92.0 | |||||
| Enterobacter spp. | ||||||
| n = 510, U.S. (124) | 2019 | 2012–2016 | 73.9b–79.8c | |||
| n = 855, Latin America (281) | 2019 | 2012–2015 | 99.2c | |||
| n = 33, Spain (279) | 2019 | 2016–2017 | 66.7b –72.7c | |||
| n = 772, Europe (285) | 2018 | 2015 | 96.8c | |||
| n = 233, China (289) | 2018 | 2012–2014 | 59.9c | |||
| n = 163, U.S. (22) | 2018 | 2017 | 100.0c | 78.4c | ||
| n = 270, U.S. (286) | 2018 | 2013–2015 | 85.5c | |||
| n = 1955, U.S. (293) | 2018 | 2013–2016 | 78.9b –83.6c | |||
| n = 159, Asia-Pacific Region (125) | 2018 | 2013–2015 | 75.5b –83.0c | |||
| n = 29, globally (180) | 2018 | 2014–2015 | 100.0c | 100.0c | ||
| n = 1,009, United Kingdom (119) | 2017 | 2011–2015 | 91.5b | |||
| n = 537, Latin America (296) | 2017 | 2013–2015 | 79.2b –84.0c | |||
| n = 118, Australia/New Zealand (297) | 2017 | 2013–2015 | 78.8b –85.6c | |||
| n = 432, Europe (295) | 2017 | 2012–2015 | 69.7c –78.0c | |||
| n = 211, U.S. (216) | 2015 | 2013–2014 | 99.0c | |||
| n = 3970, U.S. (300) | 2015 | 2011–2014 | 99.9c | |||
| Average susceptibility | 59.9–100.0 | 66.7–91.5 | 100.0 | 96.8–96.8 | ||
| Enterobacter spp., imipenem nonsusceptible | ||||||
| n = 34, Europe (285) | 2018 | 2015 | 70.6c | |||
| Enterobacteriaceae | ||||||
| n = 273, U.S. (124) | 2019 | 2012–2016 | 87.5b –90.3c | |||
| n = 1,347, globally (127) | 2019 | 2012–2016 | 89.4b –91.4c | |||
| n = 7,665, Latin America (281) | 2019 | 2012–2015 | 99.7c | |||
| n = 3,269, U.S. (276) | 2019 | 2017–2018 | 99.9b ,c | 86.9–90.1b ,c | ||
| n = 3,746, U.S. (283) | 2019 | 2015–2017 | 99.9b ,c | 95.7–96.9b ,c | ||
| n = 1,774, China (128) | 2019 | 2017 | 94.6c | 72.0c | ||
| n = 11,559, globally (178) | 2018 | 2015 | 99.3c | |||
| n = 2,362, U.S. (305) | 2018 | 2013–2015 | 90.6c | |||
| n = 2,647, U.S. (286) | 2018 | 2013–2015 | 95.5c | |||
| n = 45,872, globally (247) | 2018 | 2012–2015 | 99.4c | |||
| n = 2,125, U.S. (22) | 2018 | 2015–2017 | 100.0c | |||
| n = 694, U.S. (22) | 2018 | 2017 | 100.0c | 92.0c | ||
| n = 509, globally (84) | 2018 | 99.2c | ||||
| n = 18,656, U.S. (37) | 2018 | 2015–2016 | 99.9c | |||
| n = 31,512, U.S. (291) | 2018 | 2011–2015 | 99.9c | |||
| n = 15,223, U.S. (293) | 2018 | 2013–2016 | 92.5b –94.4c | |||
| n = 1,474, Asia-Pacific Region (125) | 2018 | 2013–2015 | 85.8b –89.2c | |||
| n = 991, globally (180) | 2018 | 2014–2015 | 98.2c | 99.0c | ||
| n = 3,419, U.S. (208) | 2018 | 2016 | 96.1d | |||
| n = 1,878, Latin America (296) | 2017 | 2013–2015 | 80.9b –84.2c | |||
| n = 36,380, U.S. (24) | 2017 | 2013–2016 | 99.9b ,c | |||
| n = 6,209, U.S. (30) | 2017 | 2011–2015 | 99.9b ,c | |||
| n = 5,950, Europe (295) | 2017 | 2012–2015 | 91.3b –93.5c | |||
| n = 1,019, Australia/New Zealand (297) | 2017 | 2013–2015 | 95.9b –97.7c | |||
| n = 6,773, U.S. (326) | 2016 | 2012–2014 | >99.9c | |||
| n = 1,312, U.S. (327) | 2016 | 2012–2014 | 99.9c | |||
| Average susceptibility | 94.6–100.0 | 72.0–97.7 | 99.0–99.3 | 96.1 | ||
| Enterobacteriaceae, ESBL | ||||||
| n = 1,701, Latin America (281) | 2019 | 2012–2015 | 99.9c | |||
| n = 391, U.S. (283) | 2019 | 2015–2017 | 100.0b ,c | 83.2–88.8b ,c | ||
| n = 285, U.S. (276) | 2019 | 2017–2018 | 100.0b ,c | 76.8–84.1b ,c | ||
| n = 271, U.S. (286) | 2018 | 2013–2015 | 87.1b | |||
| n = 1,474, Asia-Pacific Region (125) | 2018 | 2013–2015 | 70.4b –79.1c | |||
| n = 1,450, U.S. (293) | 2018 | 2013–2016 | 79.3b –87.5c | |||
| n = 906, Europe (295) | 2017 | 2012–2015 | 74.9b –82.8c | |||
| n = 67, Australia/New Zealand (297) | 2017 | 2013–2015 | 88.1b –97.0c | |||
| n = 495, Latin America (296) | 2017 | 2013–2015 | 66.9b –74.7c | |||
| Average susceptibility | 99.9–100.0 | 66.9–97.0 | ||||
| Enterobacteriaceae, OXA-48 | ||||||
| n = 45,872, globally (247) | 2018 | 2012–2015 | 92.5c | |||
| Carbapenem-resistant Enterobacteriaceae | ||||||
| n = 131, U.S. (182) | 2020 | 2014–2018 | 98.5–100.0c | |||
| n = 216, Italy (306) | 2020 | 2016–2017 | 91.6b | |||
| n = 97, China (307) | 2020 | 78.4c | ||||
| n = 79, U.S. (276) | 2019 | 2017–2018 | 97.5b ,c | 2.6b ,c | ||
| n = 28, U.S. (283) | 2019 | 2015–2017 | 89.3b ,c | 0.0b ,c | ||
| n = 372, China (128) | 2019 | 2017 | 75.3c | 6.2c | ||
| n = 62, U.S. (308) | 2019 | 2013–2016 | 87.1c | 27.4c | 79.0c | 71.0c |
| n = 120, U.S. (309) | 2019 | 82.0c | 98.0c | |||
| n = 330, globally (178) | 2018 | 2015 | 73.9c | |||
| n = 37, U.S. (305) | 2018 | 2013–2015 | 2.7c | |||
| n = 50, U.S. (22) | 2018 | 2015–2017 | 100.0c | |||
| n = 238, U.S. (37) | 2018 | 2015–2016 | 97.5c | |||
| n = 286, U.S. (293) | 2018 | 2013–2016 | 2.4b –4.5c | |||
| n = 513, U.S. (24) | 2017 | 2013–2016 | 97.5b ,c | |||
| Average susceptibility | 75.3–100.0 | 0.0–27.4 | 73.9–100.0 | 71.0 | ||
| KPC-producing Enterobacteriaceae | ||||||
| n = 103, U.S. (218) | 2018 | 100.0c | 100.0c | |||
| Klebsiella spp. | ||||||
| n = 95, Spain (279) | 2019 | 2016–2017 | 66.3b –72.9c | |||
| n = 692, U.S. (286) | 2018 | 2013–2015 | 93.1c | |||
| n = 223, U.S. (22) | 2018 | 2017 | 100.0c | 96.0c | ||
| n = 627, U.S. (305) | 2018 | 2013–2015 | 85.8c | |||
| n = 594, Asia-Pacific Region (125) | 2018 | 2013–2015 | 80.8b –84.7c | |||
| n = 1,296, U.K. (119) | 2017 | 2011–2015 | 97.6b | |||
| n = 1,112, Europe (295) | 2017 | 2012–2015 | 78.2b –82.1c | |||
| n = 246, Australia/New Zealand (297) | 2017 | 2013–2015 | 96.3b –98.8c | |||
| n = 1,484, U.S. (298) | 2016 | 2012–2014 | 99.9c | |||
| Average susceptibility | 99.9–100.0 | 66.3–98.8 | ||||
| Klebsiella pneumoniae | ||||||
| n = 280, globally (127) | 2019 | 2012–2016 | 80.0b –83.6c | |||
| n = 2,128, Latin America (281) | 2019 | 2012–2015 | 99.5c | |||
| n = 100, Taiwan (282) | 2019 | 2016–2019 | 100.0c | 80.0c | ||
| n = 863, U.S. (276) | 2019 | 2017–2018 | 100.0b ,c | 88.6–91.9b ,c | ||
| n = 666, China (128) | 2019 | 2017 | 93.8c | 52.7c | ||
| n = 1,591, Europe (285) | 2018 | 2015 | 94.9c | |||
| n = 2,458, globally (178) | 2018 | 2015 | 97.0c | |||
| n = 564, China (289) | 2018 | 2012–2014 | 74.2c | |||
| n = 123, globally (84) | 2018 | 98.4c | ||||
| n = 3,796, U.S. (37) | 2018 | 2015–2016 | 99.9c | |||
| n = 6,803, U.S. (291) | 2018 | 2011–2015 | 99.9c | |||
| n = 2,979, U.S. (293) | 2018 | 2013–2016 | 88.7b –90.6c | |||
| n = 570, Asia-Pacific Region (125) | 2018 | 2013–2015 | 80.2b –84.2c | |||
| n = 233, Germany (310) | 2018 | 2014–2015 | 99.1b | |||
| n = 878, globally (180) | 2018 | 2014–2015 | 98.2c | 98.9c | ||
| n = 717, U.S. (208) | 2018 | 2016 | 99.4d | |||
| n = 238, U.S. (294) | 2017 | 2015 | 91.7c | |||
| n =34, globally (225) | 2017 | 2012–2015 | 100.0c | |||
| n = 594, Latin America (296) | 2017 | 2013–2015 | 60.4b –64.6c | |||
| n = 917, Europe (295) | 2017 | 2012–2015 | 75.8b –79.3c | |||
| n = 190, Australia/New Zealand (297) | 2017 | 2013–2015 | 96.8b –98.4c | |||
| n = 891, U.S. (216) | 2015 | 2013–2014 | 99.3c | |||
| n = 1205, U.S. (123) | 2015 | 2013–2014 | 89.0c | |||
| Average susceptibility | 74.2–100.0 | 52.7–99.1 | 97.0–98.9 | 94.9–100.0 | ||
| Klebsiella pneumoniae, ESBL | ||||||
| n = 20, Poland (311) | 2019 | 2017 | 65.0b | |||
| n = 22, Spain (279) | 2019 | 2016–2017 | 59.1b –77.3c | |||
| n = 843, globally (178) | 2018 | 2015 | 91.2c | |||
| n = 49, U.S. (286) | 2018 | 2013–2015 | 73.5c | |||
| n = 1,474, Asia-Pacific Region (125) | 2018 | 2013–2015 | 56.6b –69.4c | |||
| n = 40, Germany (310) | 2018 | 2014–2015 | 62.5b | |||
| n = 119, U.K. (119) | 2017 | 2011–2015 | 84.0b | |||
| n = 226, Latin America (296) | 2017 | 2013–2015 | 46.0b –56.6c | |||
| n = 12, Australia/New Zealand (297) | 2017 | 2013–2015 | 66.7b –83.3c | |||
| n = 373, Europe (295) | 2017 | 2012–2015 | 41.6b –49.1c | |||
| n = 207, U.S. (298) | 2016 | 2012–2014 | 99.5c | |||
| Average susceptibility | 99.5 | 41.6–84.0 | 91.2 | |||
| Klebsiella pneumoniae, MDR | ||||||
| n = 2,821, globally (312) | 2016 | 2012–2014 | 96.6c | |||
| Klebsiella pneumoniae, carbapenem resistant | ||||||
| n = 872, China (71) | 2020 | 2017 | 96.3c | |||
| n = 19, Spain (279) | 2019 | 2016–2017 | 0.0b –5.0c | |||
| n = 295, Greece (212) | 2019 | 2015–2016 | 99.7b | 8.0b | ||
| n = 267, China (128) | 2019 | 2107 | 85.0c | 1.9c | ||
| n = 203, U.S. (293) | 2018 | 2013–2016 | 0.5b –2.5c | |||
| Average susceptibility | 85.0–99.7 | 0.0–5.0 | 8.0 | |||
| Klebsiella pneumoniae, imipenem nonsusceptible | ||||||
| n = 179, Europe (285) | 2018 | 2015 | 54.2c | |||
| Escherichia coli | ||||||
| n = 435, U.S. (124) | 2019 | 2012–2016 | 96.1b –96.6c | |||
| n = 608, globally (127) | 2019 | 2012–2016 | 96.9b –97.5c | |||
| n = 209, Spain (279) | 2019 | 2016–2017 | 95.2b –96.2c | |||
| n = 2,705, Latin America (281) | 2019 | 2012–2015 | 99.9c | |||
| n = 100, Taiwan (282) | 2019 | 2016–2019 | 99.0c | 88.0c | ||
| n = 565, U.S. (276) | 2019 | 2017–2018 | 100.0b ,c | 95.3–96.4b ,c | ||
| n = 618, China (128) | 2019 | 2017 | 96.8c | 90.5c | ||
| n = 4,921, globally (178) | 2018 | 2015 | 99.8c | |||
| n = 441, U.S. (305) | 2018 | 2013–2015 | 98.0c | |||
| n = 1,306, U.S. (286) | 2018 | 2013–2015 | 98.5c | |||
| n = 674, China (289) | 2018 | 2012–2014 | 98.7c | |||
| n = 144, U.S. (22) | 2018 | 2017 | 100.0c | 95.8c | ||
| n = 323, globally (84) | 2018 | 100.0c | ||||
| n = 7,111, U.S. (37) | 2018 | 2015–2016 | >99.9c | |||
| n = 10,471, U.S. (291) | 2018 | 2011–2015 | >99.9c | |||
| n = 6281, U.S. (293) | 2018 | 2013–2016 | 97.6b –98.6c | |||
| n = 568, Asia-Pacific Region (125) | 2018 | 2013–2015 | 92.6b –94.5c | |||
| n = 202, Germany (310) | 2018 | 2014–2015 | 96.0b | |||
| n = 35, globally (180) | 2018 | 2014–2015 | 100.0c | 100.0c | ||
| n = 1,321, U.S. (208) | 2018 | 2016 | 100.0d | |||
| n = 159, globally (225) | 2017 | 2012–2015 | 100.0c | |||
| n = 2,676, U.K. (119) | 2017 | 2011–2015 | 99.7b | |||
| n = 661, Latin America (296) | 2017 | 2013–2015 | 95.0b –96.7c | |||
| n = 3,460, Europe (295) | 2017 | 2012–2015 | 98.0b | |||
| n = 497, Australia/New Zealand (297) | 2017 | 2013–2015 | 99.8b –100.0c | |||
| n = 2,876, U.S. (298) | 2016 | 2012–2014 | 100.0c | |||
| n = 2,778, U.S. (216) | 2015 | 2013–2014 | 100.0c | |||
| n = 1,306, U.S. (123) | 2015 | 2013–2014 | 98.0c | |||
| Average susceptibility | 96.8–100.0 | 88.0–100.0 | 99.8–100.0 | 100.0 | ||
| Escherichia coli, ESBL | ||||||
| n = 31, Poland (311) | 2019 | 2017 | 93.5b | |||
| n = 116, U.S. (124) | 2019 | 2012–2016 | 66.4b –80.2c | |||
| n = 46, Spain (279) | 2019 | 2016–2017 | 80.4b –84.8c | |||
| n = 976, globally (178) | 2018 | 2015 | 99.2c | |||
| n = 153, U.S. (286) | 2018 | 2013–2015 | 92.8c | |||
| n = 966, U.S. (293) | 2018 | 2013–2016 | 86.5b –92.2c | |||
| n = 198, Asia-Pacific Region (125) | 2018 | 2013–2015 | 82.3b –87.9c | |||
| n = 281, U.K. (119) | 2017 | 2011–2015 | 97.9b | |||
| n = 32, Germany (310) | 2017 | 2014–2015 | 81.3b | |||
| n = 238, Latin America (296) | 2017 | 2013–2015 | 87.0b –91.6c | |||
| n = 559, Europe (295) | 2017 | 2012–2015 | 87.8b –92.7c | |||
| n = 47, Australia/New Zealand (297) | 2017 | 2013–2015 | 97.9b –100.0c | |||
| n = 330, U.S. (298) | 2016 | 2012–2014 | 100.0c | |||
| Average susceptibility | 100.0 | 66.4–100.0 | 99.2 | |||
| Proteus spp. | ||||||
| n = 19, Spain (279) | 2019 | 2016–2017 | 100.0b ,c | |||
| n = 182, China (289) | 2018 | 2012–2014 | 95.6c | |||
| Acinetobacter baumannii | ||||||
| n = 486, Europe (285) | 2018 | 2015 | 10.3c | |||
| n = 158, U.S. (216) | 2015 | 2013–2014 | 51.0c | |||
| Average susceptibility | 10.3–51.0 | |||||
| Acinetobacter baumannii, OXA-23 | ||||||
| n = 58, U.S. (216) | 2015 | 2013–2014 | 12.0c | |||
a
CAZ-AVI, ceftazidime-avibactam; TOL-TAZ, ceftolozane–tazobactam; MER-VAB, meropenem-vaborbactam; IMI-REL, imipenem-relebactam.
b
EUCAST-approved breakpoints applied.
c
CLSI-approved breakpoints applied.
d
MICs interpreted using CLSI breakpoints for imipenem.